Patient Perception Study for AL-4943A

Overview

To evaluate patient perceptions of Al-4943 in subjects with allergic conjunctivitis previously treated with a topical ocular anti-allergy leukotriene-release inhibitor medication.

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: N/A
    • Intervention Model: Single Group Assignment
    • Primary Purpose: Treatment
    • Masking: None (Open Label)
  • Study Primary Completion Date: October 2011

Interventions

  • Drug: AL-4943A
    • Once daily topical ocular allergy medication used for 7 days

Arms, Groups and Cohorts

  • Experimental: AL-4943A
    • One drop per day in both eyes

Clinical Trial Outcome Measures

Primary Measures

  • Overall Patient satisfaction
    • Time Frame: 7 days

Participating in This Clinical Trial

Inclusion Criteria

  • History of allergic conjunctivitis within last 24 months – Active signs and symptoms of ocular allergies Exclusion Criteria:

  • Severe or serious ocular condition, ocular surgical intervention, ocular infection

Gender Eligibility: All

Minimum Age: 12 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Alcon Research
  • Provider of Information About this Clinical Study
    • Sponsor

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.